SOFIVA GENOMICS Co (ROCO:6615) Current Deferred Revenue: NT$0.8 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ROCO:6615 SOFIVA GENOMICS Co Ltd ROCO:6615
74 GF Score
Price NT$33.70
GF Value NT$31.55
Valuation Fairly Valued
! 3 Warning Signs
View Full Analysis

What is SOFIVA GENOMICS Co Current Deferred Revenue?

SOFIVA GENOMICS Co ROCO:6615 +1.04% 74 Current Deferred Revenue is NT$0.8 Mil as of Jun. 2026. GuruFocus rates ROCO:6615 with a GF Score™ of 74/100 and a GF Value™ of NT$31.55 (Fairly Valued). The stock has 3 warning signs investors should review.

Current Deferred Revenue represents collections of cash or other assets related to revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP. It can be either current or non-current item. Also called unearned revenue.

SOFIVA GENOMICS Co's current deferred revenue for the quarter that ended in Jun. 2026 was NT$0.8 Mil.

SOFIVA GENOMICS Co Current Deferred Revenue Related Terms

SOFIVA GENOMICS Co Current Deferred Revenue Historical Data

* Premium members only.

The historical data trend for SOFIVA GENOMICS Co's Current Deferred Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

SOFIVA GENOMICS Co Current Deferred Revenue Chart

SOFIVA GENOMICS Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Current Deferred Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.69 2.11 0.77 1.77 1.18

SOFIVA GENOMICS Co Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Current Deferred Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.25 0.80 1.18 0.61 0.84
ROCO:6615
74GF Score
SOFIVA GENOMICS Co Ltd ROCO:6615
Current Deferred Revenue is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Current Deferred Revenue of NT$0.8 Mil mean?
SOFIVA GENOMICS Co (ROCO:6615) has a Current Deferred Revenue of NT$0.8 Mil as of Jun. 2026. Current Deferred Revenue records the total amount of cash received for unfinished services. View historical data on SOFIVA GENOMICS Co and its competitors.
Is SOFIVA GENOMICS Co's Current Deferred Revenue too high?
SOFIVA GENOMICS Co's current Current Deferred Revenue is NT$0.8 Mil. Overall, SOFIVA GENOMICS Co has a GF Score™ of 74/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does SOFIVA GENOMICS Co's Current Deferred Revenue compare to TMO and DHR?
SOFIVA GENOMICS Co's Current Deferred Revenue of NT$0.8 Mil can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Deferred Revenue for a Medical Diagnostics & Research company?
A good Current Deferred Revenue depends on the Medical Diagnostics & Research industry context. However, Current Deferred Revenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Deferred Revenue mean?
A high Current Deferred Revenue can signal that a stock is expensive relative to its fundamentals. Current Deferred Revenue records the total amount of cash received for unfinished services. View historical data on SOFIVA GENOMICS Co and its competitors. SOFIVA GENOMICS Co's current Current Deferred Revenue is NT$0.8 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is SOFIVA GENOMICS Co stock overvalued right now?
Based on GuruFocus' analysis, SOFIVA GENOMICS Co (ROCO:6615) is currently considered Fairly Valued. The stock's GF Value™ is NT$31.55, compared to a current price of NT$33.70 — trading 6.8% above its estimated fair value. The current Current Deferred Revenue is NT$0.8 Mil. SOFIVA GENOMICS Co's overall GF Score™ is 74/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Deferred Revenue calculated?
Current Deferred Revenue is calculated from a company's financial statements. For SOFIVA GENOMICS Co (ROCO:6615), the current Current Deferred Revenue is NT$0.8 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is SOFIVA GENOMICS Co (ROCO:6615) Overvalued in 2026?

Based on GuruFocus' analysis, SOFIVA GENOMICS Co stock appears to be overvalued. The current stock price of NT$33.70 is trading 6.8% above its estimated GF Value™ of NT$31.55. GuruFocus considers SOFIVA GENOMICS Co to be Fairly Valued.

Key valuation signals for ROCO:6615:

  • Current Deferred Revenue: NT$0.8 Mil
  • GF Value™: NT$31.55 vs. price of NT$33.70 (6.8% above fair value)
  • GF Score™: 74/100 with 3 warning signs

No single metric tells the full story. See the ROCO:6615 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

SOFIVA GENOMICS Co Business Description

Address No. 66-1, Section 1, Chongqing S. Road, 4th Floor, Zhongzheng District, Taipei, TWN, 10043
SOFIVA GENOMICS Co Ltd provides medical diagnostic services. The services offered by the company include Prenatal, Reproductive, Cancer, Precision Medicine, Newborn, and Rare Diseases. Its testing categories include Genetic, Biochemical, and Chromosome. The business items of Sofiva Group are pre-pregnancy, prenatal, and neonatal genetic testing and medical testing, and other service income. Geographically, it generates the vast majority of its revenue from Taiwan.
74GF Score

Get the complete analysis for ROCO:6615

Current Deferred Revenue is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$33.70
Price
NT$31.55
GF Value